Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ciprofol + esketamine
- Development stage
- Unknown
- Lead developer
- Haisco Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
ciprofol + esketamine is a combination anesthetic regimen consisting of ciprofol (HSK3486), a novel GABA_A receptor agonist, and esketamine, the S-enantiomer of ketamine which acts as an NMDA receptor antagonist. Ciprofol is a 2,6-disubstituted phenol derivative developed by Haisco Pharmaceutical Group as a more potent alternative to propofol with a potentially improved safety profile, including reduced respiratory and cardiovascular depression. Esketamine provides analgesic and sedative effects while maintaining sympathetic tone. The combination is being evaluated in clinical trials, such as NCT05861427, for anesthesia induction and maintenance in elderly patients undergoing procedures like endoscopic retrograde cholangiopancreatography (ERCP) to minimize intraoperative hypotension and hypoxemia.
- Brand names
- CipofolKetanest S
- Other names
- ciprofol + es-ketaminecyclopropofol + esketamineHSK3486 + esketamine
02
Targets
GABRR (GABA-A receptor subunit rho)HTR1B (5-Hydroxytryptamine Receptor 1B)σR (Sigma receptors)NMDAR (Glutamate receptor ionotropic, NMDA)HCN1 (Hyperpolarization-activated cyclic nucleotide-gated potassium channel 1)
Beyond the preview
Go deeper on ciprofol + esketamine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ciprofol + esketamine.